Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Figure 3

Specific knockdown of Survivin expression with shRNA significantly promotes paclitaxel-induced apoptosis in a trastuzumab-resistant breast cancer cell line. BT474-HR20 cells infected with lentivirus containing either control shRNA (ConshRNA) or Survivin shRNA (Survivin-S3, Survivin-S5) were subjected to the following experiments. (A) Western blot analyses of Survivin, Bcl-xL, Mcl-1, or β-actin. (B and C) The cells were then untreated, or treated with paclitaxel (8 nmol/L) for 24 h. The cells were collected and subjected to (B) western blot analyses of poly(ADP-ribose) polymerase (PARP), cleaved caspase-3, or β-actin; or to (C) apoptosis ELISA. Bars represent SD.

Back to article page